Loading
A phase 2 trial of Ibrutinib and Venetoclax in chronic lymphocytic leukaemia, run by Janssen Research & Development, LLC, active and no longer recruiting.
A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia is a phase 2 interventional study registered as NCT05963074 by Janssen Research & Development, LLC, with 333 participants enrolled, started 2024-05-30 and due to reach its primary completion in 2027-12-15. Interventions recorded: Ibrutinib and Venetoclax.
Shares Chronic lymphocytic leukaemia, first treatment, AbbVie (incl. ImmunoGen, Capstan), Venetoclax, Chronic lymphocytic leukaemia and the tag pipeline.
Shares Chronic lymphocytic leukaemia, first treatment, Venetoclax, Chronic lymphocytic leukaemia, Small-molecule kinase inhibitors and the tag pipeline.
Shares AbbVie (incl. ImmunoGen, Capstan), Venetoclax, Chronic lymphocytic leukaemia, Small-molecule kinase inhibitors and the tag pipeline.
Shares AbbVie (incl. ImmunoGen, Capstan), Venetoclax, Chronic lymphocytic leukaemia, Small-molecule kinase inhibitors and the tag pipeline.
Shares AbbVie (incl. ImmunoGen, Capstan), Venetoclax, Chronic lymphocytic leukaemia, Small-molecule kinase inhibitors and the tag pipeline.
Shares Chronic lymphocytic leukaemia, first treatment, Venetoclax, Chronic lymphocytic leukaemia, Small-molecule kinase inhibitors and the tag pipeline.
Shares Ibrutinib, Chronic lymphocytic leukaemia, Small-molecule kinase inhibitors and the tag pipeline.
Shares Chronic lymphocytic leukaemia, first treatment, Venetoclax, Chronic lymphocytic leukaemia, Small-molecule kinase inhibitors and the tag pipeline.